Related Experiment Video
Updated: Feb 22, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions
Ke Li1,2, Haibo Cheng3,4,5, Zhang Li1,2
1SIBS (Institute of Health Sciences), Changzheng Hospital Joint Center for Translational Medicine, Institute of Health Sciences, Shanghai Changzheng Hospital, Institutes for Translational Medicine (CAS-SMMU), University of Chinese Academy of Sciences, Shanghai, China.
Abstract:
Gastrointestinal stromal tumors (GISTs) are the most common sarcomas in humans. Constitutively activating mutations in the KIT or PDGFRA receptor tyrosine kinases are the initiating oncogenic events. Most metastatic GISTs respond dramatically to therapies with KIT/PDGFRA inhibitors. Asymptomatic and mitotically-inactive KIT/PDGFRA-mutant "microGISTs" are found in one third of adults, but most of these small tumors never progress to malignancy, underscoring that a progression of oncogenic mutations is required. Recent studies have identified key genomic abnormalities in GIST progression. Novel insights into the genetic progression of GISTs are shedding new light on therapeutic innovations.
Insights
Gastrointestinal stromal tumors (GISTs) arise from mutations in KIT or PDGFRA. Further genomic changes are needed for GIST progression, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastrointestinal stromal tumors (GISTs) are the most common human sarcomas.
- Activating mutations in KIT or PDGFRA receptor tyrosine kinases initiate GIST development.
- Metastatic GISTs often respond well to KIT/PDGFRA inhibitors.
Purpose of the Study:
- To explore the genomic landscape of GIST progression.
- To identify key genetic abnormalities driving malignant transformation from microGISTs.
- To inform novel therapeutic strategies for GISTs.
Main Methods:
- Genomic analysis of GIST samples.
- Identification of recurrent mutations and copy number alterations.
- Correlation of genomic findings with tumor progression and clinical data.
Main Results:
- MicroGISTs with KIT/PDGFRA mutations are common but rarely progress.
- Specific genomic alterations are associated with malignant progression of GISTs.
- Understanding GIST genetic progression is crucial for effective treatment.
Conclusions:
- GIST progression requires a stepwise accumulation of oncogenic mutations beyond initial KIT/PDGFRA activation.
- Identifying these key genomic events opens avenues for targeted therapies.
- Novel insights into GIST genetics promise improved therapeutic innovations.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
